BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35118711)

  • 21. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.
    Yamashita Y; Shimada A; Yamada T; Yamaji K; Hori T; Tsurusawa M; Watanabe A; Kikuta A; Asami K; Saito AM; Horibe K
    Pediatr Blood Cancer; 2013 Oct; 60(10):1587-92. PubMed ID: 23804397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
    Kang H; Chen IM; Wilson CS; Bedrick EJ; Harvey RC; Atlas SR; Devidas M; Mullighan CG; Wang X; Murphy M; Ar K; Wharton W; Borowitz MJ; Bowman WP; Bhojwani D; Carroll WL; Camitta BM; Reaman GH; Smith MA; Downing JR; Hunger SP; Willman CL
    Blood; 2010 Feb; 115(7):1394-405. PubMed ID: 19880498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
    Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
    Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
    Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
    Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
    Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.
    Clappier E; Auclerc MF; Rapion J; Bakkus M; Caye A; Khemiri A; Giroux C; Hernandez L; Kabongo E; Savola S; Leblanc T; Yakouben K; Plat G; Costa V; Ferster A; Girard S; Fenneteau O; Cayuela JM; Sigaux F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Soulier J; Cavé H
    Leukemia; 2014 Jan; 28(1):70-7. PubMed ID: 24064621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
    Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
    Huang Z; Jia Y; Ruan G; Zuo Y; Wu J; Lu A; Xue Y; Cheng Y; Zhang L
    Pediatr Hematol Oncol; 2022 Apr; 39(3):243-253. PubMed ID: 34582325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined analysis of
    Cui L; Gao C; Wang CJ; Zhao XX; Li WJ; Li ZG; Zheng HY; Wang TY; Zhang RD
    Leuk Lymphoma; 2021 Feb; 62(2):410-418. PubMed ID: 33054468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
    Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
    Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
    Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
    Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic significance of IKZF1 gene deletions in patients with B-cell acute lymphoblastic leukemia].
    Tang BQ; Cai ZH; Lin DN; Wang ZX; Liang XJ; Fan ZP; Huang F; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):235-240. PubMed ID: 35405782
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
    Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
    Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
    van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
    Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
    Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
    Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
    Zhang W; Kuang P; Li H; Wang F; Wang Y
    Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia".
    Palmi C; Lana T; Silvestri D; Savino A; Kronnie GT; Conter V; Basso G; Biondi A; Valsecchi MG; Cazzaniga G
    Haematologica; 2013 Dec; 98(12):e164-5. PubMed ID: 24323991
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
    Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.